Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen
Ulefnersen showed a statistically significant improvement against placebo on a combined measure assessing functional impairment.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance